Chip stocks fall with Nvidia after data center rev disappointment
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a biotech company with a market capitalization of $163 million, reported that Chief Financial Officer Charles W. Newton sold shares of common stock on August 11 and 12. The sales, totaling $2,784, were executed to cover tax withholding obligations from the settlement of vested restricted stock units. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 7.49.
On August 11, Newton sold 131 shares of Lyell Immunopharma at a weighted average price of $10.526, with prices ranging from $10.045 to $11.00. Following this transaction, Newton directly owns 8,895 shares, which includes 390 shares acquired through the company’s Employee Stock Purchase Plan and accounts for a 1-for-20 reverse stock split effected by Lyell Immunopharma on May 30, 2025. The stock currently trades at $10.83, significantly below its 52-week high of $32.40.
The following day, August 12, Newton sold an additional 136 shares at a weighted average price of $10.338, with prices ranging from $10.120 to $10.415 per share. After this transaction, Newton directly owns 8,759 shares.
Newton also indirectly owns 10,000 shares of Lyell Immunopharma common stock through The Charles & Lisa Newton Living Trust, where he serves as co-trustee and co-grantor.
In other recent news, Lyell Immunopharma has announced significant developments that may interest investors. The company has entered into a securities purchase agreement for a private placement, potentially raising up to $100 million. This agreement involves institutional and accredited investors, with an initial closing of approximately $50 million in common stock expected around July 25, 2025. Additionally, Lyell Immunopharma reported promising results from its LYL314 therapy for large B-cell lymphoma. The therapy demonstrated an 88% overall response rate and a 72% complete response rate in a Phase 1/2 trial. Impressively, 71% of patients achieving a complete response maintained this status for at least six months. These developments highlight Lyell Immunopharma’s ongoing efforts in advancing its clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.